GENFIT (GNFT): Net earnings per share for the last 12 months

Symbol and logo of brand Genfit SA (GNFT)

The commercialization of PBC therapy and progress in treating steatohepatitis are driving growth for Genfit S.A. (GNFT). The 12-month net income per share snapshot on GURU.Markets confirms this trend, where the -0.91 level indicates the parameter's status. This paves the way for massive revenue scalability from a single molecule, while partnerships with industry behemoths successfully diversify the drug portfolio risks.

GNFT (Genfit S.A.) Net earnings per one share for the last twelve months history from 07/04/2022 to 12/06/2025

Analytical breakdowns for Genfit S.A.

- stock price and consensus target price:
- stock exchange capitalization data:
Basic company analysis:GNFT - Genfit S.A.
Manufactured products of Genfit SA

The rolling net income per share trend reflects the actual efficiency of Genfit S.A. (GNFT), demonstrating the business's ability to generate profit per share over a one-year period. This indicator is calculated by dividing the total net income over 12 months by the number of shares, allowing investors to assess capital stability amid geopolitical risks and logistical disruptions during global clinical trials.